Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo

Mechanism of SARS-CoV-2 polymerase stalling by remdesivir

(2021) Goran Kokic et al.   Nature Communications

Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review

(2021) Bruno Silva Andrade et al.   Frontiers in Pharmacology

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

(2021) Chunlong Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2

(2021) Ewelina Weglarz-Tomczak et al.   Scientific Reports

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms

(2021) Ana C. Puhl et al.   ACS Omega

SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes

(2021) André C. Ferreira et al.   Cell Death Discovery

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19

(2021) Carolina Q Sacramento et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

(2021) Nuno R. Faria et al.   SCIENCE

Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID‐19 patients

(2021) Saeed Kalantari et al.   JOURNAL OF MEDICAL VIROLOGY

Repurposing drugs for treatment of COVID-19

(2021) Priya Venkatesan   Lancet Respiratory Medicine

SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021

(2021) Carolina Kymie Vasques Nonaka et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332

(2021) Yao Zhao et al.   Protein & Cell

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV

(2020) Jared S. Morse et al.   CHEMBIOCHEM

Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19

(2020) Hin Chu et al.   CLINICAL INFECTIOUS DISEASES

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

(2020) Yeming Wang et al.   LANCET

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

(2020) Linlin Zhang et al.   SCIENCE

COVID-19: The first documented coronavirus pandemic in history

(2020) Yen-Chin Liu et al.   Biomedical Journal

Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

(2020) Natalia Fintelman-Rodrigues et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

(2020) Chunlong Ma et al.   CELL RESEARCH

Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography

(2020) Daniel W. Kneller et al.   Nature Communications

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

(2020) Zhe Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

(2020) Alfonso Trezza et al.   Scientific Reports

Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site

(2020) Jaeyong Lee et al.   Nature Communications

Atazanavir: its role in HIV treatment

(2008) Robin Wood   Expert Review of Anti-Infective Therapy